Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous total IgG intramuscular therapy in chronic urticaria
KCT0006814Phase 2Recruiting
- Sponsor
- Autobulin Therapeutics
- Start
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of autologous immunoglobulin in chronic urticaria (CU), sponsored by Autobulin Therapeutics. Started Jan 2022; status: recruiting.
02
Drugs
autologous immunoglobulin
03
Conditions
chronic urticaria (CU)
Beyond the preview
Go deeper on KCT0006814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006814.